|
Website:
http://www.curagen.com
Phone: +1 203 481-1104 |
Address:
322 East Main Street
Branford, CONNECTICUT 06405 |
Company Description
CuraGen Corporation. The Group's principal activities are to develop therapeutics for the treatment of cancer and cancer supportive care. The Group operates in two segments through its subsidiaries : 454 Life Sciences Corporation and CuraGen. The 454 Life Sciences Corporation segment provides commercialized advanced technologies for high-throughput sequencing of DNA. The 454's sequencing technology consists of the Genome Sequencer 20 Instrument, the Genome Sequencer FLX and associated reagent kits, disposables and analysis software. The CuraGen segment develops novel protein, antibody and small molecule therapeutics for the treatment of cancer and cancer supportive care. The Group operates in the United States, Germany and Switzerland. 454 Life Sciences Corporation accounted for 93% of 2006 gross revenues and CuraGen Corporation, 7%
Key People
| President & Chief Executive | Dr. Frank M. Armstrong |
| Executive Vice President, Chief Financial Officer & Treasurer | David M. Wurzer |
| Senior Vice President Finance & Secretary | Elizabeth A. Whayland |
Related Business Topics
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
C
CuraGen
Discovery and development of life science products through the systematic application of genomics.
www.curagen.com
Discovery and development of life science products through the systematic application of genomics.
www.curagen.com
